The 2008 evidence report of the Agency for Healthcare Research and Quality (AHRQ) called for high-quality, prospective cohort studies that identified men at the time of diagnosis of localized prostate cancer (PCa) and collected comprehensive patient, tumor, and treatment selection characteristics to generate critical patient-centered information to aid in decision-making for localized disease. Although new evidence has been generated since 2008 that has advanced the understanding of outcomes following treatment for PCa, the knowledge gap identified in the AHRQ report remains unfilled.
